The platelet polymorphism PlA2 is a genetic risk factor for myocardial infarction
Key result
The Pl(A2) polymorphism was present in 35% of patients with CAD and previous MI compared to 28% of healthy individuals (P=0.002), indicating an association with increased MI risk.
Why the study?
Is the platelet polymorphism Pl(A2) associated with an increased risk of myocardial infarction?
Population
2,210 individuals from a Scandinavian population, including 1,019 patients with angiographically verified…
Comparison
Presence of the platelet polymorphism Pl(A2) vs Absence of the Pl polymorphism
Design
Case-control
Authors
Discussion
Loading...
Member takes
Implication
Pl(A2) may increase MI risk; case-control data leaves causal role and clinical utility open for prospective validation.
Study Design
Type
Case-Control (n=2,210)
Structured PICO
Is the platelet polymorphism Pl(A2) associated with an increased risk of myocardial infarction?
P
Population
2,210 individuals from a Scandinavian population, including 1,019 patients with angiographically verified CAD (529 with previous MI) and 1,191 matched healthy controls.
E
Exposure
Presence of the platelet polymorphism Pl(A2)
C
Comparator
Absence of the Pl(A2) polymorphism (or healthy controls / CAD patients without MI)
O
Outcome
Myocardial infarction (MI)hard clinical
Main Result
Absolute Event Rate: 35% vs 28%
p-value: p=0.002
The Pl(A2) polymorphism is significantly associated with an increased risk of myocardial infarction, but not of CAD without MI, in a Scandinavian population.
Cite This Study
Grove et al. (2004) conducted a case-control in Myocardial infarction (n=2,210). Pl(A2) polymorphism vs. Healthy individuals was evaluated on Presence of Pl(A2) polymorphism (p=0.002). The Pl(A2) polymorphism was present in 35% of patients with CAD and previous MI compared to 28% of healthy individuals (P=0.002), indicating an association with increased MI risk.